GlassScriptPhysician profile
Krista M Stoecker
NPI 1487032181
$2,987.62
in general payments reported to CMS, 2019-2025
31 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $326 · 2021: $391 · 2022: $254 · 2023: $521 · 2024: $558 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,605.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,089.97 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $214.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $209.27 | 2020-2024 | Breztri, Airsupra |
| Astellas Pharma US INC | $171.27 | 2019-2025 | Veozah |
| Amgen INC. | $169.87 | 2019-2021 | |
| Pfizer INC. | $159.07 | 2019-2025 | |
| Lilly USA, LLC | $117.49 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $116.99 | 2023-2025 | Rexulti, Abilify Maintena |
| Sanofi Pasteur INC. | $96.59 | 2019-2023 | |
| Glaxosmithkline, LLC. | $79.36 | 2019-2023 | Shingrix, Arexvy |
| Exact Sciences Corporation | $58.63 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $56.79 | 2019-2024 | Invega Sustenna |
| Abbott Laboratories | $48.46 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $37.11 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $36.93 | 2023-2025 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.98 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.66 | 2023-2025 | Xifaxan |
| Philips North America LLC | $30.38 | 2020 | |
| Amarin Pharma, INC. | $29.56 | 2020 | |
| Optinose US, INC. | $24.39 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.00 | 2020-2021 | |
| Dexcom, INC. | $21.92 | 2024 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $19.41 | 2025 | Rezdiffra |
| Ardelyx, INC. | $16.63 | 2024 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $16.21 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.38 | 2025 | Voquezna |
| Impel Pharmaceuticals INC. | $13.81 | 2023 | Trudhesa |
| Bayer Healthcare Pharmaceuticals INC. | $13.09 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.76 | 2019 | |
| Lundbeck LLC | $11.46 | 2020 | |
| Genentech USA, INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Stoecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.